OK, we are the NFL of prostate cancer, not like those amateurs with localized cancer...but this news is worth! First of all, if you have Candel shares, congrats! a +172% raise in stock value is not peanuts. But what made me smile, is that immune therapy (in this case using a viral vector) is starting to work in prostate cancer too...plus who knows? They may want to test it also for advanced prostate cancer?
CAN-2409, a new viral immunotherapy, has shown promising results in treating prostate cancer. In a recent phase 3 clinical trial, it significantly improved disease-free survival when used with standard radiation therapy. The therapy works by using a gene that, when combined with a prodrug, kills tumor cells and triggers an immune response against the cancer. The safety profile of CAN-2409 is favorable, with mostly mild side effects. Based on these positive results, the company developing CAN-2409 plans to seek FDA approval.
